Label X Muscle Reviews : (Muscle Formula) Should You Buy? v1

SummaryMen have a higher incidence of cardiovascular disease (CVD) than women of similar age, and it has been suggested that testosterone may influence the development of CVD. Recently, we demonstrated that elderly men with low testosterone levels had lower plasma levels of free tissue factor pathway inhibitor (TFPI) Ag associated with shortened tissue factor (TF)-induced coagulation initiation in a population based case-control study. Our hypothesis was that one year of testosterone treatment to physiological levels in elderly men would increase the levels of free TFPI Ag in plasma and have a favorable effect on TF-induced coagulation. Twenty-six men with low testosterone levels (≤11.0 nM) were randomly assigned to treatment with intramuscular testosterone depot injections (testosterone undecanoate 1,000 mg) or placebo in a double-blinded study. Each participant received a total of five injections, at baseline, 6, 16, 28 and 40 weeks, and TF-induced thrombin generation ex vivo and plasma free TFPI Ag were measured after one year. At the end of the study total and free testosterone levels were significantly higher in the testosterone treated group (14.9 ± 4.5 nM vs. 8.1 ± 2.4 nM; p<0.001, and 363.3 ± 106.6 pM vs. 187.3 ± 63.2 pM; p<0.001, respectively). Testosterone treatment for one year did neither cause significant changes in TF-induced thrombin generation ex vivo nor changes in plasma levels of free TFPI Ag. In conclusion, normalising testosterone levels by testosterone treatment for 12 months in elderly men did not affect TF-induced coagulation or plasma TFPI levels. The potential antithrombotic role of testosterone therapy remains to be elucidated.

Download Full-text

How Do We Love? Romantic Love Style in Men Is Related to Lower Testosterone Levels

Physiological Research ◽

10.33549/physiolres.933523 ◽

2017 ◽

pp. 695-703 ◽

Cited By ~ 1

Author(s):

J. BABKOVÁ DURDIAKOVÁ ◽

P. CELEC ◽

I. KOBOROVÁ ◽

T. SEDLÁČKOVÁ ◽

G. MINÁRIK ◽

...

Keyword(s):

Androgen Receptor ◽

Romantic Love ◽

Social Background ◽

Plasma Testosterone ◽

Love Styles ◽

Testosterone Levels ◽

The Family ◽

Low Testosterone ◽

And Behavior ◽

Attitudes And Behavior

Testosterone has been widely investigated in associations with many aspects of social interactions, emotions and behavior. No research has been conducted on its contribution to the variability of love styles in human. The aim of this paper was to uncover the possible relationship between not only the actual plasma testosterone levels, but also the prenatal testosterone level (expressed as 2D:4D ratio) and the sensitivity of androgen receptor and love typology in young healthy men. There are six love styles which are primary including Eros (passionate romantic love), Ludus (playful) and Storge (friendly) and secondary love consisting of Mania (obsessive), Pragma (practical realistic) and Agape (altruistic). Our results pointed out that low testosterone concentrations are associated with higher score for Eros, Ludus, Pragma, Mania love style. No significant association was proved for other tested parameters of androgenicity (2D:4D, sensitivity of androgen receptor) and love style after correction was applied. Different attitudes and behavior in relationships do have a biological foundation related to endogenous testosterone levels in plasma. Future studies should address questions about the family and social background of participants to differentiate here between moral rules or/and social-conventional rules.

Download Full-text

Normogonadotropic hypogonadism in men with obesity

Obesity and metabolism ◽

10.14341/2071-8713-5243 ◽

2009 ◽

Vol 6 (3) ◽

pp. 39-42 ◽

Cited By ~ 2

Author(s):

L V Savel'eva ◽

R V Rozhivanov ◽

B O Shurdumova ◽

V V Fadeev

Keyword(s):

Testosterone Level ◽

Healthy Subjects ◽

Immunoreactive Insulin ◽

Homa Index ◽

Obese Patients ◽

Functional Disorder ◽

Testosterone Levels ◽

Significant Difference ◽

Low Testosterone ◽

Index Calculation

Objective: to evaluate the preavalence and characteristics of hypogonadism in obese man. Research and Methods: Thestudy was performed in 31 obese man (aged 33 [22;44], BMI 40 [34,4;44,0]. Measurements during the study: chemistry panel, testosteroa and LH levels, immunoreactive insulin, HOMA index calculation. Statistically significant difference w as considered as p < 0,05. Results. Hypogonadism preavalence was 80,6%. The hypogonadism prevalence and testosterone level was more depended on age and obesity but less on duration. 100 % risk of hypogonadism w as observed in heavily obese patients. There w as no increase of LH levels. In man with low testosterone lev els HOMA index w as significantly higher со mpared to healthy subjects. Conclusion: The prevalence of normogonadotropic hypogonadism in obese men is extremely high and it represents an evidence of functional disorder of hypophyseal gonadal system. Thedecrease of testosterone levels is age-coinciding, but it is more pronounced in obese nan.

Download Full-text

Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes

Acta Endocrinologica ◽

10.1530/eje-13-0321 ◽

2013 ◽

Vol 169 (6) ◽

pp. 725-733 ◽

Cited By ~ 219

Author(s):

Vakkat Muraleedharan ◽

Hazel Marsh ◽

Dheeraj Kapoor ◽

Kevin S Channer ◽

T Hugh Jones

Keyword(s):

Type 2 Diabetes ◽

Untreated Group ◽

Testosterone Replacement ◽

Testosterone Deficiency ◽

Testosterone Levels ◽

All Cause Mortality ◽

Low Testosterone

ObjectiveMen with type 2 diabetes are known to have a high prevalence of testosterone deficiency. No long-term data are available regarding testosterone and mortality in men with type 2 diabetes or any effect of testosterone replacement therapy (TRT). We report a 6-year follow-up study to examine the effect of baseline testosterone and TRT on all-cause mortality in men with type 2 diabetes and low testosterone.Research design and methodsA total of 581 men with type 2 diabetes who had testosterone levels performed between 2002 and 2005 were followed up for a mean period of 5.8±1.3 s.d. years. Mortality rates were compared between total testosterone >10.4 nmol/l (300 ng/dl; n=343) and testosterone ≤10.4 nmol/l (n=238). The effect of TRT (as per normal clinical practise: 85.9% testosterone gel and 14.1% intramuscular testosterone undecanoate) was assessed retrospectively within the low testosterone group.ResultsMortality was increased in the low testosterone group (17.2%) compared with the normal testosterone group (9%; P=0.003) when controlled for covariates. In the Cox regression model, multivariate-adjusted hazard ratio (HR) for decreased survival was 2.02 (P=0.009, 95% CI 1.2–3.4). TRT (mean duration 41.6±20.7 months; n=64) was associated with a reduced mortality of 8.4% compared with 19.2% (P=0.002) in the untreated group (n=174). The multivariate-adjusted HR for decreased survival in the untreated group was 2.3 (95% CI 1.3–3.9, P=0.004).ConclusionsLow testosterone levels predict an increase in all-cause mortality during long-term follow-up. Testosterone replacement may improve survival in hypogonadal men with type 2 diabetes.

Download Full-text

Low testosterone is associated with disability in men with multiple sclerosis

Multiple Sclerosis Journal ◽

10.1177/1352458514527864 ◽

2014 ◽

Vol 20 (12) ◽

pp. 1584-1592 ◽

Cited By ~ 52

Author(s):

R Bove ◽

A Musallam ◽

BC Healy ◽

K Raghavan ◽

BI Glanz ◽

...

Keyword(s):

Multiple Sclerosis ◽

Hypogonadotropic Hypogonadism ◽

Total Testosterone ◽

Cross Sectional ◽

Testosterone Levels ◽

Vitamin D Levels ◽

Relapsing Remitting ◽

25 Hydroxy Vitamin D ◽

Male Patients ◽

Low Testosterone

Background: Gonadal steroids may modulate disease course in multiple sclerosis (MS). Objective: To assess the prevalence and clinical associations of hypogonadism in men with MS. Methods: Male patients, aged 18–65 years, with relapsing–remitting MS (RRMS) or clinically-isolated syndrome (CIS) and their first symptom < 10 years prior were selected from a longitudinal clinical study. We measured their hormones in stored morning blood samples, and collected their Expanded Disability Status Scale (EDSS) scores every 6 months and their Symbol Digit Modalities Test (SDMT) results annually. Results: Our analysis included 96 men with a mean age of 40 years, EDSS of 1.1 and disease duration of 4.6 years. Of these men, 39% were hypogonadal (total testosterone < 288 ng/dL); none showed compensatory elevations in luteinizing hormone. Their low testosterone levels and testosterone:estradiol ratios were negatively correlated with body mass index (BMI) and leptin, and showed no correlation with 25-hydroxy-vitamin D levels. In our primary cross-sectional analyses, there was a negative age-adjusted correlation between total testosterone and EDSS ( p = 0.044). In the age-adjusted longitudinal analyses, higher baseline testosterone levels were associated with less decline in SDMT ( p = 0.012). Conclusions: Men with MS may experience hypogonadotropic hypogonadism. Low testosterone levels may be associated with worse clinical outcomes. A potential neuroprotective role for testosterone warrants further investigation.

Download Full-text